miR‑143‑5p suppresses breast cancer progression by targeting the HIF‑1α‑related GLUT1 pathway

Xu,Jia; Li,Xi; Zhang,Purong; Luo,Jie; Mou,Exian; Liu,Shiwei

doi:10.3892/ol.2022.13268

miR‑143‑5p suppresses breast cancer progression by targeting the HIF‑1α‑related GLUT1 pathway

Authors:
- Jia Xu
- Xi Li
- Purong Zhang
- Jie Luo
- Exian Mou
- Shiwei Liu
View Affiliations

Affiliations: Department of Breast Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China, Department of Plastic Surgery, Chengdu First People's Hospital, Chengdu, Sichuan 610041, P.R. China, Department of Breast Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China
Published online on: March 15, 2022 https://doi.org/10.3892/ol.2022.13268
Article Number: 147
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is a commonly identified life‑threatening type of cancer and a major cause of death among women worldwide. Several microRNAs (miRs), including miR‑143‑5p, have been reported to be vital for regulating hallmarks of cancer; however, the effect of miR‑143‑5p on BC requires further exploration. The present study performed bioinformatics analysis on GSE42072 and GSE41922 datasets from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database to identify miR‑143‑5p expression patterns. Furthermore, miR‑143‑5p expression was detected in BC cell lines and tissues via reverse transcription‑quantitative PCR. Post‑transfection with miR‑143‑5p mimics, Cell Counting Kit‑8, colony formation and Transwell assays were performed to explore the effects of miR‑143‑5p on BC cell proliferation, colony formation, and migration. The association of miR‑143‑5p with the hypoxia‑inducible factor‑1α (HIF‑1α)‑associated glucose transporter 1 (GLUT1) pathway was explored via western blotting, immunofluorescence and dual‑luciferase reporter assay. The present study detected high expression of miR‑143‑5p in BC tissue of the GSE42072 and serum of the GSE41922 datasets by GEO chip analysis. Additionally, the expression levels of miR‑143‑5p were decreased in BC tissues compared with those in adjacent healthy tissues, and low miR‑143‑5p expression was associated with a poorer prognosis and shorter survival time in patients with BC. In vitro, miR‑143‑5p expression levels were decreased in BC cells, and transfection with miR‑143‑5p mimics suppressed BC cell proliferation, colony formation, migration. Furthermore, miR‑143‑5p targeted the HIF‑1α‑related GLUT1 pathway, and inhibited HIF‑1α and GLUT1 expression. Additionally, HIF‑1α agonists reversed the miR‑143‑5p‑induced inhibition during tumorigenesis. In conclusion, miR‑143‑5p exhibited low expression in BC tissues, and suppressed BC cell proliferation, colony formation, migration. Moreover, the antitumor effects of miR‑143‑5p targeted the HIF‑1α‑related GLUT1 pathway.

View Figures

View References

1	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Smith RA, Caleffi M, Albert US, Chen TH, Duffy SW, Franceschi D and Nyström L; Global Summit Early Detection and Access to Care Panel, . Breast cancer in limited-resource countries: Early detection and access to care. Breast J. 12 (Suppl 1):S16–S26. 2006. View Article : Google Scholar : PubMed/NCBI
4	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lee MC and Jagsi R: Postmastectomy radiation therapy: Indications and controversies. Surg Clin North Am. 87511–526. (xi)2007. View Article : Google Scholar : PubMed/NCBI
6	Danish Breast Cancer Cooperative Group, . Nielsen HM, Overgaard M, Grau C, Jensen AR and Overgaard J: Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish breast cancer cooperative group DBCG 82 b and c randomized studies. J Clin Oncol. 24:2268–2275. 2006. View Article : Google Scholar : PubMed/NCBI
7	Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 97:116–126. 2005. View Article : Google Scholar : PubMed/NCBI
8	Weigelt B, Peterse JL and van't Veer LJ: Breast cancer metastasis: Markers and models. Nat Rev Cancer. 5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
10	Bach DH, Lee SK and Sood AK: Circular RNAs in cancer. Mol Ther Nucleic Acids. 16:118–129. 2019. View Article : Google Scholar : PubMed/NCBI
11	Gandellini P, Doldi V and Zaffaroni N: microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Semin Cancer Biol. 44:132–140. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
13	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
14	Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
15	Liu Q, Peng F and Chen J: The role of exosomal MicroRNAs in the tumor microenvironment of breast cancer. Int J Mol Sci. 20:38842019. View Article : Google Scholar : PubMed/NCBI
16	Asiaf A, Ahmad ST, Arjumand W and Zargar MA: MicroRNAs in breast cancer: Diagnostic and therapeutic potential. Methods Mol Biol. 1699:23–43. 2018. View Article : Google Scholar : PubMed/NCBI
17	Troschel FM, Böhly N, Borrmann K, Braun T, Schwickert A, Kiesel L, Eich HT, Götte M and Greve B: miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumour Biol. 40:10104283187918872018. View Article : Google Scholar : PubMed/NCBI
18	Soheilyfar S, Velashjerdi Z, Sayed Hajizadeh Y, Fathi Maroufi N, Amini Z, Khorrami A, Haj Azimian S, Isazadeh A, Taefehshokr S and Taefehshokr N: In vivo and in vitro impact of miR-31 and miR-143 on the suppression of metastasis and invasion in breast cancer. J BUON. 23:1290–1296. 2018.PubMed/NCBI
19	Chen C, Liu X, Chen C, Chen Q, Dong Y and Hou B: Clinical significance of let-7a-5p and miR-21-5p in patients with breast cancer. Ann Clin Lab Sci. 49:302–308. 2019.PubMed/NCBI
20	Li M, Zou X, Xia T, Wang T, Liu P, Zhou X, Wang S and Zhu W: A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med. 8:7006–7017. 2019. View Article : Google Scholar : PubMed/NCBI
21	Wang C, Pang L, Shi Q, Liu X and Liu Y: The diagnostic value of serum miR-129 in breast cancer patients with bone metastasis. Clin Lab. 66:1904382020. View Article : Google Scholar
22	Shao Y, Yao Y, Xiao P, Yang X and Zhang D: Serum miR-22 could be a potential biomarker for the prognosis of breast cancer. Clin Lab. 65:2019. View Article : Google Scholar
23	Zhang HL, Wang XX and Zhang F: Correlations of the MiR-330 expression with the pathogenesis and prognosis of breast cancer. Eur Rev Med Pharmacol Sci. 23:1584–1590. 2019.PubMed/NCBI
24	Anwar SL, Sari DNI, Kartika AI, Fitria MS, Tanjung DS, Rakhmina D, Wardana T, Astuti I, Haryana SM and Aryandono T: Upregulation of circulating MiR-21 expression as a potential biomarker for therapeutic monitoring and clinical outcome in breast cancer. Asian Pac J Cancer Prev. 20:1223–1228. 2019. View Article : Google Scholar : PubMed/NCBI
25	Wang J, Song C, Tang H, Zhang C, Tang J, Li X, Chen B and Xie X: miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 19:722017. View Article : Google Scholar : PubMed/NCBI
26	He M, Zhan M, Chen W, Xu S, Long M, Shen H, Shi Y, Liu Q, Mohan M and Wang J: MiR-143-5p deficiency triggers EMT and metastasis by targeting HIF-1α in gallbladder cancer. Cell Physiol Biochem. 42:2078–2092. 2017. View Article : Google Scholar : PubMed/NCBI
27	Sanada H, Seki N, Mizuno K, Misono S, Uchida A, Yamada Y, Moriya S, Kikkawa N, Machida K, Kumamoto T, et al: Involvement of dual strands of miR-143 (miR-143-5p and miR-143-3p) and their target oncogenes in the molecular pathogenesis of lung adenocarcinoma. Int J Mol Sci. 20:44822019. View Article : Google Scholar : PubMed/NCBI
28	Liu C, Wang JO, Zhou WY, Chang XY, Zhang MM, Zhang Y and Yang XH: Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p. Mol Cell Endocrinol. 493:1104242019. View Article : Google Scholar : PubMed/NCBI
29	Wu F, Gao H, Liu K, Gao B, Ren H, Li Z and Liu F: The lncRNA ZEB2-AS1 is upregulated in gastric cancer and affects cell proliferation and invasion via miR-143-5p/HIF-1α axis. Onco Targets Ther. 12:657–667. 2019. View Article : Google Scholar : PubMed/NCBI
30	Yu X, Hu L, Li S, Shen J, Wang D, Xu R and Yang H: Long non-coding RNA taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p. Cell Death Dis. 10:2802019. View Article : Google Scholar : PubMed/NCBI
31	Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, Vocadlo DJ, Seagroves TN and Reginato MJ: O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell. 54:820–831. 2014. View Article : Google Scholar : PubMed/NCBI
32	Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH and Lee AS: Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 19:4477–4487. 2013. View Article : Google Scholar : PubMed/NCBI
33	Tang S, Wei L, Sun Y, Zhou F, Zhu S, Yang R, Huang Y, Zhang H, Xu H and Yang J: CA153 in breast secretions as a potential molecular marker for diagnosing breast cancer: A meta analysis. PLoS One. 11:e01630302016. View Article : Google Scholar : PubMed/NCBI
34	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
35	Li X, Zeng Z, Wang J, Wu Y, Chen W, Zheng L, Xi T, Wang A and Lu Y: MicroRNA-9 and breast cancer. Biomed Pharmacother. 122:1096872020. View Article : Google Scholar : PubMed/NCBI
36	Zhao W, Geng D, Li S, Chen Z and Sun M: LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer Med. 7:842–855. 2018. View Article : Google Scholar : PubMed/NCBI
37	Zhao B, Song X and Guan H: CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a/b-3p-COL5A1 axis. Life Sci. 244:1171792020. View Article : Google Scholar : PubMed/NCBI
38	Ren S, Liu J, Feng Y, Li Z, He L, Li L, Cao X, Wang Z and Zhang Y: Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia. J Exp Clin Cancer Res. 38:3882019. View Article : Google Scholar : PubMed/NCBI
39	Ardila HJ, Sanabria-Salas MC, Meneses X, Rios R, Huertas-Salgado A and Serrano ML: Circulating miR-141-3p, miR-143-3p and miR-200c-3p are differentially expressed in colorectal cancer and advanced adenomas. Mol Clin Oncol. 11:201–207. 2019.PubMed/NCBI
40	Toda H, Seki N, Kurozumi S, Shinden Y, Yamada Y, Nohata N, Moriya S, Idichi T, Maemura K, Fujii T, et al: RNA-sequence-based microRNA expression signature in breast cancer: Tumor-suppressive miR-101-5p regulates molecular pathogenesis. Mol Oncol. 14:426–446. 2020. View Article : Google Scholar : PubMed/NCBI
41	García-Vazquez R, Ruiz-García E, Meneses García A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda A, Maldonado-Martínez H, González-Barrios JA, Campos-Parra AD, Rodríguez Cuevas S, et al: A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol. 39:10104283177028992017. View Article : Google Scholar : PubMed/NCBI
42	Caritg O, Navarro A, Moreno I, Martínez-Rodenas F, Cordeiro A, Muñoz C, Ruiz-Martinez M, Santasusagna S, Castellano JJ and Monzó M: Identifying high-risk stage II colon cancer patients: A three-MicroRNA-based score as a prognostic biomarker. Clin Colorectal Cancer. 15:e175–e182. 2016. View Article : Google Scholar : PubMed/NCBI
43	Li RL, He LY, Zhang Q, Liu J, Lu F, Duan HX, Fan LH, Peng W, Huang YL and Wu CJ: HIF-1α is a potential molecular target for herbal medicine to treat diseases. Drug Des Devel Ther. 14:4915–4949. 2020. View Article : Google Scholar : PubMed/NCBI
44	Xia Y, Jiang L and Zhong T: The role of HIF-1α in chemo-/radioresistant tumors. Onco Targets Ther. 11:3003–3011. 2018. View Article : Google Scholar : PubMed/NCBI
45	Ioannou M, Paraskeva E, Baxevanidou K, Simos G, Papamichali R, Papacharalambous C, Samara M and Koukoulis G: HIF-1α in colorectal carcinoma: Review of the literature. J BUON. 20:680–689. 2015.PubMed/NCBI
46	Brooks DL, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, Schörg A, Gotwald L, Fan M, Wenger RH and Seagroves TN: ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer. 15:262016. View Article : Google Scholar : PubMed/NCBI
47	Byun Y, Choi YC, Jeong Y, Lee G, Yoon S, Jeong Y, Yoon J and Baek K: MiR-200c downregulates HIF-1α and inhibits migration of lung cancer cells. Cell Mol Biol Lett. 24:282019. View Article : Google Scholar : PubMed/NCBI
48	Li H, Jia Y and Wang Y: Targeting HIF-1α signaling pathway for gastric cancer treatment. Pharmazie. 74:3–7. 2019.PubMed/NCBI
49	Amann T and Hellerbrand C: GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 13:1411–1427. 2009. View Article : Google Scholar : PubMed/NCBI
50	Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A and Saavedra E: Energy metabolism in tumor cells. FEBS J. 274:1393–1418. 2007. View Article : Google Scholar : PubMed/NCBI
51	Gu NJ, Wu MZ, He L, Wang XB, Wang S, Qiu XS, Wang EH and Wu GP: HPV 16 E6/E7 up-regulate the expression of both HIF-1α and GLUT1 by inhibition of RRAD and activation of NF-κB in lung cancer cells. J Cancer. 10:6903–6909. 2019. View Article : Google Scholar : PubMed/NCBI
52	Song K, Li M, Xu XJ, Xuan L, Huang GN, Song XL and Liu QF: HIF-1α and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia. Asian Pac J Cancer Prev. 15:1823–1829. 2014. View Article : Google Scholar : PubMed/NCBI
53	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
54	Chen C, Pore N, Behrooz A, Ismail-Beigi F and Maity A: Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 276:9519–9525. 2001. View Article : Google Scholar : PubMed/NCBI
55	Murakami T, Nishiyama T, Shirotani T, Shinohara Y, Kan M, Ishii K, Kanai F, Nakazuru S and Ebina Y: Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes. J Biol Chem. 267:9300–9306. 1992. View Article : Google Scholar : PubMed/NCBI
56	Ebert BL, Firth JD and Ratcliffe PJ: Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem. 270:29083–29089. 1995. View Article : Google Scholar : PubMed/NCBI
57	Wang E, Zhang C, Polavaram N, Liu F, Wu G, Schroeder MA, Lau JS, Mukhopadhyay D, Jiang SW, O'Neill BP, et al: The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PLoS One. 9:e861022014. View Article : Google Scholar : PubMed/NCBI